Approval · Notice of Compliance 29909 · 2023
MINT-LACOSAMIDE: Notice of Compliance 29909
Issued January 16, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29909
- Date
- January 16, 2023
- Company
- Mint Pharmaceuticals IncMississauga, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to the Product Monograph. Product Monograph reformatted to the Master Template
- Canadian reference product
- VIMPAT (Ucb Canada Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| MINT-LACOSAMIDE | Not yet assigned | — |
Medicinal ingredients
- LACOSAMIDE 50 MG per TAB
- LACOSAMIDE 100 MG per TAB
- LACOSAMIDE 150 MG per TAB
- LACOSAMIDE 200 MG per TAB